Browsed by
Tag: Algernon

Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific …

Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific …

VANCOUVER, British Columbia, Oct. 09, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Dr. Mark Swaim, a former practicing physician and researcher has joined the Algernon Medical and Scientific Advisory Board.

Dr. Mark Swaim, MD, PhD graduated from Duke University with honours, where he was an NIH-sponsored Medical Scientist Training Program scholar, and was elected to the Alpha Omega Alpha Honor Medical Society and served as its president. He completed post-graduate training in internal medicine, gastroenterology and hepatology at Duke University Medical Center and post-doctoral research at National Taiwan University in Taipei. Dr. Swaim served on the faculties of Duke University Medical Center, University of Texas MD Anderson Cancer Center and the McGovern Medical School of University of Texas in Houston. He was elected to fellowship in the American College of Physicians. He is editor-in-chief and founder of  BioPub.co a small-cap biotech special situations investing website with a global following.

Update on South Korea COVID Trial

Due to a lack of sufficiently ill patients, which is a direct result of a highly-successful government initiated pandemic mitigation strategy, the Company has decided to close the investigator-led South Korea trial. Instead, the Company will remain focused on its Phase 2b/3 multinational Ifenprodil COVID study, which currently has enrolled more than 75% of its target enrollment.

The Company has projected that the multinational Phase 2b/3 study will be completed in November 2020, with a planned data readout before the end of Q4, 2020.

“I am very pleased that Dr. Swaim has accepted our invitation to join our Advisory Board and we look forward to working closely with him,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “We also look forward to reaching

Read the rest
Algernon Pharmaceuticals Inc. | AGNPF Stock Message Board & Forum

Algernon Pharmaceuticals Inc. | AGNPF Stock Message Board & Forum

RE:One Last Thing…

Thanks Algernon, I often enjoy many of your posts but definitely your tone has been extremely negative. I am not opposed to negative comments as there could be valuable information. For the record I hold a substantial position in AGN.

I quickly checked the insider tab here and I do not see Kal Malhi listed. I am assuming he does have 11% position with 15 million shares. I would like your opinion why you feel he controls the movement of the stock in either direction. If he is truly an insider he is subject to blackout periods and all insider trades are monitored and recorded yet I do not see any listed here under insiders tab.

You also indicate some for of relationship with AGN Ceo and Mr Malhi being his boss and some form of control. Can you please explain in detail what you are suggesting.

Can you also connect the dots with other companies you mention with regards to AGN or any of its management and the relevance to such?

My last comment has to do with patent protection. Are you suggesting they do not have legal rights to repurpose the drugs they are working? Why do you feel that? Do all pharmaceutical companies list their patents? Could the patent be held under a numbered company controlled by AGN. 

Your recent posts which are rather negative and warning shareholders and creating a lot of doubt do not provide back up to support your comments.

You are suggesting that readers contact the CEO and your email does not provide accurate email for Mr. Moreau. Have you contacted him and received a reply to your comments, if so please share with us.

Source Article Read the rest